Cytori Partner Kerastem Completes Enrollment of US Phase II Trial for Early Stage Hair Loss

SAN DIEGO–(BUSINESS WIRE)–Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that its
licensee Kerastem Technologies, LLC, has completed enrollment of STYLE,
a US phase II clinical trial investigating early stage female and male
pattern hair loss.

“Cytori Cell Therapy is a broadly applicable cell therapeutic platform
used now in multiple mid and late stage clinical trials in the US, Japan
and Europe. Our partner Kerastem is focused on developing Cytori
technology for men and women with alopecia,” said Dr. Marc H. Hedrick,
President & CEO of Cytori. “Early proof of concept clinical data has
shown promise and Kerastem expects a read out from the trial in
approximately one year. This therapy if approved could create a
significant value for our stockholders.”

STYLE is a phase II randomized, blinded, and controlled investigation of
Kerastem therapy in early stage female and male pattern baldness. A
total of four clinical trial sites treated a target enrollment of 70
patients in the United States. The primary endpoint of STYLE is safety
and tolerability at six months and subjects will be followed for 12
months. Subjects participating in STYLE received one of four treatment
arms, including fat plus ADRCs.

Outside of the United States, Kerastem is actively involved in market
development, with Kerastem therapy currently being offered at a number
of clinics in Europe & Japan.

To learn more about Kerastem or the STYLE Clinical Trial, please visit

About Cytori

Cytori Therapeutics is a late stage cell therapy company developing
autologous cell therapies from adipose tissue to treat a variety of
medical conditions. Data from preclinical studies and clinical trials
suggest that Cytori Cell Therapy™ acts principally by improving blood
flow, modulating the immune system, and facilitating wound repair. As a
result, Cytori Cell Therapy™ may provide benefits across multiple
disease states and can be made available to the physician and patient at
the point-of-care through Cytori’s proprietary technologies and
products. For more information visit

About Kerastem

Kerastem Technologies, LLC is a private company owned by Bimini
Technologies, and holds global rights to commercialize Cytori Cell
Therapy for alopecia and hair related indications. The Bimini portfolio
of products also includes Puregraft, the world’s leading fat grafting

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements, including, without
limitation, statements regarding STYLE clinical data and potential
benefits to Cytori and its stockholders if Cytori Cell Thearapy is
approved for alopecia, are all subject to risks and uncertainties that
could cause our actual results and financial position to differ
materially. Some of these risks and uncertainties include, but are not
limited to, inherent risk and uncertainty in the protection intellectual
property rights, regulatory uncertainties, risks in the conduct of
clinical trials (including clinical trial conducted by third parties),
risks in the collection and results of clinical data, final clinical
outcomes, dependence on third party performance, performance (including
performance under and compliance with the terms of our contracts with
such third parties) and acceptance of our products in the marketplace,
as well as other risks and uncertainties described under the heading
“Risk Factors” in Cytori’s Securities and Exchange Commission Filings on
Form 10-K and Form 10-Q. We assume no responsibility to update or revise
any forward-looking statements to reflect events, trends or
circumstances after the date they are made.


Cytori Therapeutics, Inc.
Tiago Girao, +1 858-458-0900